Health Canada Clears Cytokinetics’ MYQORZO for Obstructive HCM
The Canadian authorization covers adults with symptomatic class II-III disease and follows positive results from a Phase 3 trial.
Makkler Newsroom · Oct 19, 02:53 PM · 1 min read
Cytokinetics, Incorporated CYTK
NASDAQHealth TechnologyUnited States
$56.13-0.03 (-0.05%)
Market closed· · USD · Data may be delayed
- Day's range
- 55.1556.66
- 52-week range
- 53.5588.31
Financial health
– / 5
Analyst view · 23 firms
Buy21 buy · 2 hold · 0 sell
Avg. target $109.42 (+94.9%)
Prices may be delayed and are for informational purposes only - not investment advice.